Follow Us

Stay in touch with us on social media!

  • Facebook

  • Twitter

  • Google+

  • LinkedIn

  • YouTube

  • Pinterest

  • Instagram

Say Hello To The New Global Coherence App – A Unique Way To Facilitate Collective Heart Coherence Learn More

Research Library
Publication

Inherited Ventricular Arrhythmias, the Channelopathies and SCD: Current Knowledge and Future Speculations – Risk Stratification, Management Plans and Future Speculations

    • Published: 2020
    • Abdullah Abdulrhman Al Abdulgader1
    • IntechOpen, 2020.1. Senior Congenital Cardiologist and Invasive Electrophysiologist, Prince Sultan Cardiac Center, Alhasa, Hofuf, Saudi Arabia. DOI: 10.5772/intechopen.92131.
    • Download the complete paper, click here.

Abstract

Channelopathy constitutes significant proportion of SCD worldwide (around 10% or 370,000 deaths annually). It was creating a mysterious group of diseases until the second half of the last century when Anton Jervell and Fred Lange-Nielsen described Jervell Lange-Nielsen syndrome in 1957. It was late until 1995 where genetic characterization commenced. Later on, the massive genetic information with the discovery of genetic heterogeneity and allelic het¬erogeneity was a major victory in the field. The basic sciences in cellular electrophysiology and genetics complemented by meticulous clinical detection and the different clinical trials in the field opened a new era of wide therapeutic choices for clinicians. The knowledge obtained from the different experimental platforms especially the induced pluripotent stem cells is promising. The revolutionary move in SCD and channelopathies is described where correlation between the arrhythmogenesis and fluctuation in SGMA is established and must be investigated. The observation of the arrhythmogenicity of SGMA fluctuation and its effect on HRV together with the differential effect of certain sympathovagal tones (more sympathetic innervation is favoring VT/VF in LQTS1, LQTS2 and SQTS but not BrS or ERS) are all future directions to optimize our preventive, diagnostic as well as therapeutic options of SCD and channelopathy in humans.